Vaccine Technology Platforms Advantages and Limitations

This white paper discusses the advantages and limitations of various vaccine technology platforms. It outlines the historical evolution of vaccine manufacturing, beginning with the smallpox vaccine in 1796 and continuing through the recent advancements spurred by the COVID-19 pandemic. The document categorizes vaccine platforms into traditional and novel approaches, detailing their mechanisms, benefits, and challenges. Traditional vaccines, such as whole pathogens and subunits, are contrasted with next-generation platforms like viral vectors and genetic vaccines. The paper emphasizes the unique properties of each platform, including their efficacy, safety, and manufacturing complexities. It also presents a pipeline of over 800 vaccine candidates across various indications, highlighting the industry's ongoing innovation and investment in modern vaccine technologies. The discussion includes insights from industry experts on the factors influencing platform selection for vaccine development and distribution, underscoring the importance of adaptability in addressing public health needs.